Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

07.06.2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

 

ASH 2018: ECHELON-2 trial

11.12.2018

Prof. Lorenz Trümper about the ECHELON-2 trial.

  • 5 min
 

Quarterly Focus on Hematology | CLL

10.01.2019

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented. In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL. Guests Prof. Arnon Kater, MD, PhD Hematologist, Amsterdam UMC (AMC), The Netherlands Prof. Stephan Stilgenbauer, MD Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany Gert Jan Timmers, MD, PhD Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands Prof. Paolo Ghia, MD, PhD Internist, Università Vita-Salute San Raffaele, Milan, Italy Kostas Stamatopoulos, MD, PhD CERTH, Thessaloniki, Greece   Publications to be discussed Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018 Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019 About our "Quarterly Focus" format Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

 

ASH 2018: Highlights

11.12.2018

Prof. Anas Younes summarizes some of his highlights of ASH 2018.

  • 5 min
 

Meet the Author: prof. dr. Mark Levis

18.06.2020

In this e-learning, author prof. dr. Mark Levis will be queried about the ADMIRAL trial by an expert panel of hematologists, led by prof. dr. Gerwin Huls. They will discuss the ADMIRAL trial in relapsed / refractory acute myeloid leukemia. In this phase III trial, the FLT3-inhibitor gilteritinib was compared to salvage chemotherapy treatment of relapse or refractory acute myeloid leukemia with a mutation in the FLT3 gene. This program provides the opportunity to gain thorough understanding of the ADMIRAL trial. Together with the key author, the expert panel will offer profound insight into how this study was setup and executed. In addition, they will discuss the results of the trial and assess how these could impact daily clinical practice.   Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML Perl AE, Martinelli G, Levis MJ, et al. N Engl J Med 2019; 381:1728-1740 Author prof. Mark Levis, MD - hematologist, Johns Hopkins Medicine, Baltimore, USA Speakers prof. Gerwin Huls, MD - hematologist, UMCG, Groningen, The Netherlands; prof. Marc Raaijmakers, MD - hematologis, Erasmus MC, Rotterdam, The Netherlands; Saskia Klein, MD, PhD - hematologist, MeanderMC, Amersfoort, The Netherlands

Click here to select your areas of interest

Areas of interest

Select to filter on program types